Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Gelmon, KA
  • Hirte, Holger
  • Robidoux, A
  • Tonkin, KS
  • Tischkowitz, M
  • Swenerton, K
  • Huntsman, D
  • Carmichael, J
  • Macpherson, E
  • Oza, AM

publication date

  • May 20, 2010